BACE1 and Alzheimer disease: BACE-1 inhibition isa promising avenue for slowing AD progression, which affects a person’sability to perform daily tasks.−,  AD has been classified as a multifactorialdisease, with risk factors including increasing age, genetics, headinjuries, vascular diseases, infections, and environmental factorssuch as heavy and trace metals. Othersymptoms include difficulties speaking, solving problems, and othercognitive skills. Now, AD is a commonform of dementia, and around the world, approximately 55 million peoplehave this disease.